We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $677M
1-Year Est. Return 322.07%
This Fund
S&P 500
This Quarter Est. Return
+22.16%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$104M
AUM Growth
+$3.52M
Cap. Flow
-$16.5M
Cap. Flow %
-15.91%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$12.6M
2
KURA icon
Kura Oncology
KURA
+$3.85M

Sector Composition

Rank Sector Weight
1 Healthcare 99.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RUBY
1
DELISTED
Rubius Therapeutics, Inc
RUBY
$47.4M 45.77%
2,618,351
– –
KURA icon
2
Kura Oncology
KURA
$916M
$26.6M 25.74%
1,606,307
-250,000
-13% -$3.85M
FATE icon
3
Fate Therapeutics
FATE
$291M
$22.4M 21.6%
1,273,190
-800,000
-39% -$12.6M
CHMA
4
DELISTED
Chiasma, Inc. Common Stock
CHMA
$6.22M 6.01%
1,196,776
– –
BLPH
5
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$631K 0.61%
64,377
– –
AKAO
6
DELISTED
Achaogen Inc
AKAO
$285K 0.28%
624,544
– –

Similar funds

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
NCM
Noesis Capital Mangement Boca Raton, Florida $676M AUM 34.17% 1-Year Est. Return
TWM
Topsail Wealth Management Charlotte, North Carolina $678M AUM 13.87% 1-Year Est. Return
DLIC
Daido Life Insurance Company Osaka, Japan $678M AUM 16.09% 1-Year Est. Return
REAM
Ripple Effect Asset Management New York $679M AUM 81.6% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Arch Venture Management's Q1 2019 Portfolio in Review

As of Q1 2019, Arch Venture Management held 6 positions worth $104M, up 3.5% from $100M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Arch Venture Management withdrew a net $16.5M in Q1 2019, reducing 2 holdings. Its largest reduction was Fate Therapeutics, cutting an estimated $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

  • Arch Venture Management's biggest Q1 2019 reduction was Fate Therapeutics, cutting an estimated $12.6M.
  • Arch Venture Management's ten largest holdings make up 100% of its $104M portfolio in Q1 2019.
  • Arch Venture Management opened 0 new positions and closed 0 in Q1 2019.
  • Arch Venture Management's portfolio value rose 3.5% quarter-over-quarter to $104M.

Based on Arch Venture Management's 13F filing for Q1 2019, filed 14 May 2019.